Olson J A, Silverman S
J Oral Pathol. 1978;7(6):393-9. doi: 10.1111/j.1600-0714.1978.tb01608.x.
Forty-eight patients with diagnosed recurrent aphthous stomatitis participated in a randomized double-blind study of levamisole therapy. Each patient's response to treatment was determined by the following criteria: (1) days between attacks, (2) duration of lesions, (3) patient's self-evaluation of pain, (4) investigator's clinical evaluation of patient's subjective treatment response. Statistical analysis of the levamisole and placebo groups of criteria 1 and 2 above revealed no significant difference. In contrast to the above findings, analysis of the investigator's recordings of patient's subjective treatment response showed that 26% of the levamisole patients experienced marked or moderate improvement. None of the placebo patients were recorded as having experienced the same degree of benefit. Fourteen of 15 patients who complained of side effects were taking levamisole. The most common side effects were dysgeusia and hyperosmia.
48名确诊为复发性阿弗他口炎的患者参与了左旋咪唑治疗的随机双盲研究。每位患者对治疗的反应由以下标准确定：（1）发作间隔天数，（2）病变持续时间，（3）患者对疼痛的自我评估，（4）研究者对患者主观治疗反应的临床评估。对上述标准1和2的左旋咪唑组和安慰剂组进行统计分析，结果显示无显著差异。与上述发现相反，对研究者记录的患者主观治疗反应的分析表明，26%的左旋咪唑治疗患者有显著或中度改善。安慰剂组患者均未记录有相同程度的获益。15名抱怨有副作用的患者中有14名正在服用左旋咪唑。最常见的副作用是味觉障碍和嗅觉过敏。
